Skip to main content
Telo Genomics Corp. logo

Telo Genomics Corp. — Investor Relations & Filings

Ticker · TELO ISIN · CA87975M2085 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 289 across all filing types
Latest filing 2026-04-14 Regulatory Filings
Country CA Canada
Listing TSXV TELO

About Telo Genomics Corp.

https://www.telodx.com/

Telo Genomics Corp. is a molecular diagnostics company specializing in developing predictive and prognostic solutions utilizing its proprietary telomere-based platform. The core technology, TeloView®, quantifies genomic instability by measuring the 3D structure and spatial organization of telomeres. This platform is designed to provide actionable information regarding disease aggressiveness and potential response to treatment, helping to tailor therapeutic approaches. Applications focus primarily on multiple cancers (oncology) and neurodegenerative diseases (CNS). The company is pioneering the most comprehensive telomere platform in the industry to address unmet market needs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 90% confidence The document is a corporate press release announcing exploration drill results (sonic drill assays, sampling highlights, resource estimation plans) and marketing contract details. It is not an earnings release, management discussion, or formal financial report; instead, it is a general market/regulatory announcement distributed to exchanges. No specific category (e.g., earnings, M&A, share issuance) applies, making it a fallback Regulatory Filing (RNS).
2026-04-14 English
News release - English.pdf
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing a new clinical study collaboration and CAP laboratory accreditation. It contains no financial results, no voting or management changes, no capital transactions, and is not an investor presentation or regulatory report itself. It is a general corporate announcement best fitting the fallback category of Regulatory Filings (RNS).
2026-04-14 English
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a corporate press release announcing the appointment of a new CEO and Chairman, the engagement of an investor relations service provider, option grants related to that appointment, and the resignation of the Executive Chairman and director. These are changes in senior management and board composition, fitting the Board/Management Information category. There is no indication of detailed financial results, earnings, or regulatory filings beyond the management changes. Therefore, the correct classification is MANG.
2026-03-31 English
News release - English.pdf
Board/Management Information Classification · 92% confidence The document is a press release announcing the appointment of a new CEO and Chairman, the engagement of a new investor relations service provider, and the resignation of a director. These are changes to the company’s senior management and board. This aligns with the Board/Management Information category (MANG).
2026-03-31 English
Material change report - English.pdf
Regulatory Filings
2026-03-18 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings
2026-03-17 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.